Figure 4: The suppressed hippocampal neurogenesis induced by SCO treatment was restored by treatment with FSJ but not SJ.

(A) Representative images of DAB immunostaining for DCX in the hippocampal DG of each 14 day drug administration are shown. DCX-positive cells were highly expressed in the nucleus and neurites in the DG. The scale bar = 100 μm. (B) The graph shows the number and neurite length of DCX-positive cells in the DG. Data are presented as the mean ± SEM (n = 5 mice/group). **p < 0.01, compared with CON-treated group; ^##p < 0.01, compared with SCO-treated group. In C and E, representative confocal z-stack images of co-localization of BrdU (green) with DCX (in C, red) or NeuN (in E, red) in brain sections of the survival group are shown. Arrows indicate double positive cells (BrdU⁺/DCX⁺ or BrdU⁺/NeuN⁺). Arrowheads indicate only BrdU⁺ cells. The scale bar = 50 μm. In (D,F) quantitative graphs show the percentage of double-labeled positive cells (BrdU⁺/DCX⁺ (in D) or BrdU⁺/NeuN⁺ (in F)). Data are presented as the mean ± SEM (n = 5 mice/group). **p < 0.01, compared with CON-treated group; ^##p < 0.01, compared with SCO-treated group.